Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Macugen Access Program Will Help Seniors With Medicare Copay

Executive Summary

The Macugen Access Program will help seniors cover the 20% Medicare copay, Eyetech COO Paul Chaney said

You may also be interested in...

Pfizer/Eyetech Macugen ASP

Pfizer/Eyetech's Macugen reimbursed at $1,054.70 per injection under Medicare Part B average sales price plus 6% model. Macugen, which FDA approved Dec. 17 for the treatment of neovascular (wet) age-related macular degeneration, carries a list price of $995 per injection (1"The Pink Sheet" Jan. 3, 2005, p. 7). Labeling recommends Macugen be administered every six weeks, bringing the treatment's annual cost based on list price to $7,960 per eye, and CMS' annual reimbursement per eye to $8,437.60 (2"The Pink Sheet" Jan. 10, 2005, p. 20)...

Tarceva, Kepivance, And Macugen Approvals Are Quiet Milestones For FDA

Genentech/OSI's Tarceva, Amgen's Kepivance and Pfizer/Eyetech's Macugen are the first three products approved under the "continuous marketing application" pilot program

Pfizer/Eyetech Macugen Clears FDA; Firms See Broad Medicare Coverage

Pfizer/Eyetech's launch of the ophthalmic agent Macugen should be helped by a relatively generous initial reimbursement under Medicare Part B





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts